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Abstract 
The ansamycin antibiotic, herbimycin A, selectively inactivates cytopiasmic tyrosine kinases, most likely by binding irreversibly to the reactive SH 
group(s) of kinases. To further investigate the mechanism of herbimycin A action, we attempted to label tyrosine kinases with [“‘Clherbimycin A. 
~60”“” and p2 10 BCR-ABL in immune complexes were labeled with [‘4C]herbimycin A, demonstrating that the antibiotic binds directly to tyrosine kinases. 
Digestion of i’“Cjherbimycin A-iabeied ~6oi-~” with Staphylococcus aureus V8 protease revealed that the herbimycin A binding site is within the 
C-terminal 26-kDa fragment of p6pc, which contains the tyrosine kinase domain. Herbimycin A treatment inhibited labeling of p60’+” by 
[‘4C]fluorosuifonyibenzoyi adenosine, an affinity labeling reagent of nucieotide binding sites, indicating that herbimycin A-modified p60”“” cannot 
interact with ATP. The results suggest hat herbimycin A inactivates tyrosine kinases by binding directly to the kinase domain, thereby inhibiting 
access to ATP. 
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1. Introduction 
The ansamycin antibiotic, herbimycin A, blocks many 
bioiogicai events mediated by tyrosine kinases ii j. It se- 
lectively reduces tyrosine kinase activities both in cells 
and in cell-free systems [l-6]. Although the precise mech- 
anism of herbimycin A action is not fully understood, the 
inhibitor irreversibly inactivates tyrosine kinases in vitro, 
and its action is abrogated by sulfhydryl compounds [6]. 
The most logical mechanism of such effect is conjugation 
between herbimycin A and reactive SH group(s) of ki- 
nases. 
In this study, we present confirming evidence for direct 
and irreversible binding of herbimycin A to ~60’~“‘” and 
P210BCR-ABL using [‘4C]herbimycin A. V8 protease cleav- 
age of [14C]herbimycin A-labeled p60”+” revealed that 
the binding site is within the tyrosine kinase domain. 
Binding of herbimycin A to ~60’~” appeared to obstruct 
access of ATP, which is likely to be the mechanism of 
inhibition. As herbimycin A is expected to bind and inac- 
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Abbreviations: FSBA, fluorosulfonylbenzoyl adenosine; HEPES, N- 
(hydroxyethyl)piperaine-K-2-ethanesulfonic a id; EDTA, ethylene 
glycoi-bis(B-aminoethyl ether)N,N,N’,N’-tetraacetic a id; DMSO, di- 
methyl sulfoxide; SDS-PAGE, sodium dodecyl sulfate-poiyacrylamide 
gel electrophoresis. 
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tivate other cytoplasmic tyrosine kinases in the same 
manner, radioisotope-labeled herbimycin A may be use- 
ful as an affinity labeling reagent for some tyrosine ki- 
nases. 
2. Materials and methods 
2.1. Materials 
[methyl-‘4C]Methionine was a product of American Radiolabeled 
Chemicals Inc. (St. Louis, MO). [‘+‘C]FSBA was from NEN Research 
Products. Monoclonai antibodies against Src (clone 327) and Abl 
(clone 24-21) were purchased from Oncogene Science Inc. (Mineoia, 
NV\ FTP&&n r&n b ,1,-o ,.,*0,..,rarl “C rlarz.r;lr,A . . ..n.r.^..nl.. r-n T14PlU-- 
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bimycin A was prepared biosynthetically by adding [methyl- 
“C]methionine to herbimycin A-producing cultures, and was purified 
using high-performance liquid chromatography prior to use in these 
experiments. The specific activity of [‘4C]Herbimycin A was IO-20 
mCi/mmoi, depending on culture conditions. 
2.2 Labeling of tyrosine kinases by [“C]herbimycin A 
NIH3T3 cells infected with the Schmidt-Ruppin D strain of Rous 
sarcoma virus (NIH3T3/v-src ceils) or K562 cells were lysed in 20 mM 
HEPES, pH 7.4, 1 mM EDTA, 0.1 mM Na,VO,, 150 mM NaCi, and 
1% Triton X-100 containing 25 ,ug/mi each of the protease inhibitors 
antipain, leupeptin, and pepstatin A. Lysates were centrifuged at 
15,000 x g for 30 min, split into two halves, and then each half was 
incubated with monoclonal antibody against Src (NIH3T3/v-src cells) 
or ABL (K562 cells) protein with rabbit anti-mouse IgG as a second 
antibody. The immune complexes were collected onto formalin-lixed 
Staphylococcus aureus, washed and suspended in 20 mM HEPES, pH 
7.4. [‘4C]Herbimycin A dissolved in DMSO was added to the immune 
complexes and incubated at 25°C for 1 h. The final concentrations of 
[‘4C]herbimycin A and DMSO were 10 @ml and 10% (v/v), respec- 
tively. The immune complexes were washed with RIPA buffer (20 mM 
Aii rights reserved. 
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HEPES, pH 7.4, 1 mM EDTA, 0.1 mM Na,VO,, 150 mM NaCl, 1% 
Triton X-100, 1% sodium deoxycholate, 0.1% SDS), and the labeled 
proteins were separated by 9% (~60’.““) or 7.5% (~210’~~-~‘~) SDS- 
PAGE and visualized using a Fujtx BAS2000 Bio-imaging Analyzer 
(Fuji Photo Film Co., Tokyo, Japan). [‘4C]Herbimycin A-labeled 
~60’“” was excised from the gel, subjected to peptide mapping with 
Staphylococcus aureu~ V8 protease [8], and the labeled fragment was 
visualized using BAS2000. 
~60’” immune complexes were treated with various concentrattons 
of herbimycin A for 30 min at 25°C washed, and suspended in 90 ,~l 
of 20 mM HEPES, pH 7.4. 10 ~1 of [14C]FSBA (1 ,UZi. 18.8 nmol) in 
DMSO was added to the suspensions, and the mixture was incubated 
for 1 h at 30°C. The treated immune complexes were washed with RIPA 
buffer and separated by 7.5% SDS-PAGE. The gel was dried without 
staining and analyzed using BAS2000. 
3. Results 
3.1. Labeling of p60”~“” and p210BCR-ABL with 
[‘4C]herbimycin A
As shown in Figs. 1A and 2, proteins of about 60 kDa 
and 210 kDa were labeled when immune complexes pre- 
pared, respectively, with anti-Src and anti-Abl monoclo- 
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nal antibodies were treated with [‘4C]herbimycin A. 
Since the bands were not observed in control immune 
complexes without monoclonal antibodies (Figs. 1A and 
2, left lanes) they are probably ~60”~“’ and p210BCR-ABL, 
respectively. The [14C]herbimycin A-labeled ~60”‘“” was 
excised from the gel and subjected to V8 protease analy- 
sis. The result shown in Fig. 1B indicates that herbimycin 
A binds to the carboxyl-terminal 26-kDa V2 fragment 
[9], which contains the tyrosine kinase domain. 
3.2. Labeling of p60’~“” with [14C]FSBA 
S-FSBA is an irreversible analog of ADP, ATP, NAD 
or NADP and is known to bind to nucleotide sites of 
various proteins [lo, 111. As shown in Fig. 3, ~60’~“” in
the immune complex was labeled when incubated with 
[14C]FSBA. Another protein of about 53 kDa was also 
labeled, but this band was observed in the control lane 
without anti-Src antibody, and is probably IgG heavy 
chain. Pretreatment of the immune complex with her- 
bimycin A inhibited the labeling of p60”-“” by [14C]FSBA. 
We confirmed that there was no loss of v-Src protein 
during incubation with herbimycin A using immune 
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Fig. 1. Labeling of ~60’.“” by [‘4C]herbimycin A. (A) v-Src was immunoprecipitated from NIH3T3/v-src cell extract and Incubated with [‘4C]herbimy- 
cm A as described in the text. The treated immune complex was subjected to 9% SDS-PAGE and analyzed using a Fujix BAS2000 Bio-imaging 
Analyzer. The left lane is a control without anti-Src antibody. Positions and sizes of molecular markers are shown to the left. (B) v-Src was cut out 
from the gel and subjected to pepttde mapping with Staphylococcus aureus V8 protease and visualized using the Fujix analyzer. Lanes: 1. [‘4C]her- 
bimycin A-labeled v-Src; 2, [35S]methionine-labeled v-Src. Positions of VI and V2 fragments are indicated on the right. Molecular markers are shown 
on the left. (C) V8 cleavage map of v-Src. Shown are positrons of the ATP binding site (K), autophosphorylation site (Y) and conserved cysteines 
(0. 
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Fig. 2. Labeling of p2 10 BCR-ABL by [‘4C]herbimycin A. p210BCR-48L was 
immunoprecipitated from KS62 cell extracts and incubated with 
[14C]herbimycin A as described in the text. The treated immune complex 
was subjected to 7.5% SDS-PAGE and analyzed using the Fujix ana- 
lyzer. The left lane is a control without anti-Abl antibody. Positions and 
sizes of molecular markers are shown to the left. 
complex prepared from [35S]methionine-labeled cells 
(data not shownj. The results suggest hat the nUC]eOtide 
pocket is masked when p60’~“” ismodified with herbimy- 
tin A. 
4. Discussion 
The tyrosine kinase inhibitor, herbimycin A, has been 
proved to be a useful reagent for analyzing various bio- 
logical events that involve tyrosine phosphorylation [12- 
181. It inactivates tyrosine kinases both in intact cells and 
cell-free in vitro systems. Previous experiments uggested 
that the most likely mechanism of inactivation is conju- 
gation between herbimycin A and the reactive SH 
group(s) of kinases [5,6,19]. In this study, we used 
[‘4C]herbimycin A to present strong evidence for direct 
binding of herbimycin A to ~60’“” and p210BcReABL. Al- 
thn..mh thn ~~PO;OD ,v4t;~-\n .S,QO nrrt o,wvl..&.,~l., TIsxtm. rllvugll Lllcl plbclla y”alLl”ll wu.7 ll”C r”urluJl”rlJ ut,Lc,- 
mined, binding of herbimycin A to the tyrosine kinase 
domain was confirmed by V8 protease cleavage of 
[‘4C]herbimycin A-labeled ~60’~“‘. 
Considering that herbimycin A inactivates many tyro- 
sine kinases, the two conserved cysteine residues in the 
kinase domain (CYSTIC and CYSTS’ in ~60”~“‘) seem the 
most probable binding sites. The significance of the con- 
served cysteine residues in tyrosine kinases was recently -_ .__ _ __^_ 
demonstrated by Veillete et al. [ZO], who aitered the cys- 
teines in ~56”~ to alanine by site-directed mutagenesis. 
Mutation of either of the conserved cysteines in ~56”~ 
(Cys4@ and CYSTIC) abolished catalytic activity of Lck. 
Furthermore, mutation of Cys475 resulted in reduced 
half-life of Lck. Herbimycin A-treatment also induces 
inactivation and degradation of cytoplasmic tyrosine ki- 
nases, and their results support the hypothesis that her- 
bimycin A acts by modifying the conserved cysteine res- 
idues of tyrosine kinases. 
As mentioned above, we and other investigators ob- 
served that herbimycin A promotes degradation of tyro- 
sine kinases in several cells [4,12,17], and such degrada- 
tion, in some cases, was presumed to be the mechanism 
of its action, For example, June et al. reported that her- 
bimycin A did not inhibit Fyn tyrosine kinase in vitro, 
and that reduction in protein amount rather than specific 
activity accounts for the inhibition of Fyn-dependent 
signal transduction by herbimycin A [12]. It should be 
noted, however, that their kinase inhibition experiment 
was performed at 4°C and conjugation of herbimycin A 
to tvrosine k_iBases in cell-free Fvstemq aiBIOst always _, _ _ L____ L,L.-___L 
requires incubation at higher temperatures [l]. We spec- 
ulate from our experimental results that the primary 
mechanism of herbimycin A is the direct inactivation of 
kinase activity, at least for cytoplasmic tyrosine kinases. 
Degradation may also contribute, however, and appears 
to be the main mode of action against EGF receptor 
tyrosine kinase of A431 cells (unpublished observations). 
In this case, herbimycin A does not inhibit the tyrosine 
kinase activity of the EGF receptor, but decreases EGF 
receptor number by promoting degradation of immature 
receptors, resulting in an altered response of the cells to 
EGF. The mechanism of accelerated egradation has not 
been conclusively determined but we speculate that it is 
a consequence of direct binding of herbimycin A to EGF 
receptors during the maturation process. It is possible 
that in some cells, herbimycin A-modified tyrosine ki- 
nases are recognized as abnormal proteins and thus se- 
lectively degraded. 
Labeling of ~60”~“’ by [14C]FSBA, an affinity labeling 
reagent of nucleotide sites, was inhibited by preincuba- 
tion with herbimycin A, implying that the nucleotide 
binding site is masked in the herbimycin A-treated 
~60”~““. The ATP binding site of ~60”~“” is LYS~~‘s which 
is about 200 residues N-terminal from the predicted her- 
anti-&c Ab - + + + + 
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Fig. 3. Inhibition of [14C]FSBA binding to p60’“” by herbimycin A. 
v-Src immune complexes were pretreated with various concentrations 
of herbimycin A, and then incubated with [14C]FSBA (1 ,&i, 18.8 nmol 
in a volume of 100 ~1). Treated immune complexes were subjected to 
7.5% SDS-PAGE and analyzed using the Fujix analyzer. The leftmost 
lane is a control without anti-Src antibody. HMA, herbimycin A. 
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bimycin A binding sites. Although not close to the ATP 
binding site in the primary structure, we speculate that 
the conserved cysteines are positioned within or in the 
vicinity of the nucleotide pocket, and that herbimycin A 
binding impairs ATP access, consequently inactivating 
tyrosine kinase activity. It is possible that the tertiary 
conformation of the kinases is critical for herbimycin A 
action. In this report, we have presented data of her- 
bimycin A binding to activated forms of tyrosine kinases. 
According to the current model, normal forms of tyro- 
sine kinases are negatively regulated, due to changes in 
tertiary structure resulting from the interaction of 
phosphorylated C-terminal tyrosine with the SH2 do- 
ma& ;n tha ~m;nn tmmin~l v-~&fin UXIhathnr the n-n . ..Ulll “1 Cl&s, LIllllll” L~LIII‘IICLI IV61”ll. I. llrLLLb1 cuti CIvu- 
served cysteines in such forms of tyrosine kinases are 
accessible to herbimycin A is not clear at present. 
Of the known tyrosine kinase inhibitors, herbimycin 
A is the only compound reported to bind covalently to 
the target enzymes. [‘4C]Herbimycin A may thus be use- 
ful as an affinity labeling reagent for some tyrosine ki- 
nases, and we are currently investigating such use. 
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